BDTX Stock Summary and Trading Ideas (Black Diamond Therapeutics | NASDAQ:BDTX)

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.

As of April 2, 2026, BDTX stock price climbed to $2.39 with 525,057 million shares trading.

BDTX has a beta of 1.66, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.17 to the broad based SPY ETF.

BDTX has a market cap of $136.92 million. This is considered a Micro Cap stock.

In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.

The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, VXF, FESM, IBB, BSVO.

BDTX has outperformed the market in the last year with a price return of +60.4% while the SPY ETF gained +18.2%. BDTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -1.6% and +10.1%, respectively, while the SPY returned -3.6% and -0.6%, respectively.

BDTX support price is $2.21 and resistance is $2.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.